Saraswati Sukumar
Overview
Explore the profile of Saraswati Sukumar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
168
Citations
12042
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Visvanathan K, Cimino-Mathews A, Fackler M, Karia P, VandenBussche C, Orellana M, et al.
Breast J
. 2025 Jan;
2022:9533461.
PMID: 39741654
Introduction: Critical regulatory genes are functionally silenced by DNA hypermethylation in breast cancer and premalignant lesions. The objective of this study was to examine whether DNA methylation assessed in random...
2.
Fackler M, Pleas M, Li Y, Soni A, Xing D, Cope L, et al.
Clin Epigenetics
. 2024 Apr;
16(1):56.
PMID: 38643219
Background: Cervical cancer remains a leading cause of death, particularly in developing countries. WHO screening guidelines recommend human papilloma virus (HPV) detection as a means to identify women at risk...
3.
Li B, Qi F, Zhu F, Lu Z, Wang M, Chu T, et al.
Cancer Res
. 2023 Jun;
83(17):2924-2937.
PMID: 37326467
Significance: A smart nanomedicine encapsulating fulvestrant to improve its half-life, bioavailability, and tumor-targeting and coloaded with CDK4/6 inhibitor abemaciclib to block resistance is a safe and effective therapy for ER-positive...
4.
Visvanathan K, Cope L, Fackler M, Considine M, Sokoll L, Carey L, et al.
Clin Cancer Res
. 2022 Dec;
29(4):784-790.
PMID: 36534524
Purpose: We previously demonstrated that high levels of circulating methylated DNA are associated with subsequent disease progression in women with metastatic breast cancer (MBC). In this study, we evaluated the...
5.
Pai P, Wang G, Teo W, Raez-Rodriguez D, Gabrielson K, Gyorffy B, et al.
Cancer Res
. 2022 Sep;
82(20):3802-3814.
PMID: 36166646
Significance: Loss of HOXA5 reduces IκBα stability and increases NF-κB signaling to exacerbate breast cancer aggressiveness, providing new insights into the tumor suppressor functions of HOXA5.
6.
Fackler M, Tulac S, Venkatesan N, Aslam A, de Guzman T, Mercado-Rodriguez C, et al.
Cancer Res Commun
. 2022 Sep;
2(6):391-401.
PMID: 36046124
Current molecular liquid biopsy assays to detect recurrence or monitor response to treatment require sophisticated technology, highly trained personnel, and a turnaround time of weeks. We describe the development and...
7.
Liu J, Guo L, Rao Y, Zheng W, Gao D, Zhang J, et al.
Int J Nanomedicine
. 2022 Jun;
17:2661-2678.
PMID: 35733417
Purpose: Triple-negative breast cancer (TNBC) is challenging to treat with traditional "standard of care" therapy due to the lack of targetable biomarkers and rapid progression to distant metastasis. Methods: We...
8.
Wang G, Kumar A, Ding W, Korangath P, Bera T, Wei J, et al.
Proc Natl Acad Sci U S A
. 2022 Jun;
119(24):e2200200119.
PMID: 35675429
The human transferrin receptor (TFR) is overexpressed in most breast cancers, including preneoplastic ductal carcinoma in situ (DCIS). HB21(Fv)-PE40 is a single-chain immunotoxin (IT) engineered by fusing the variable region...
9.
Downs B, Sukumar S
ACS Appl Mater Interfaces
. 2022 May;
14(21):24113-24121.
PMID: 35603357
Many studies have established that blood-based liquid biopsies can be used to detect cancer in its early stages. However, the limiting factor for early cancer detection is the volume of...
10.
Smith Y, Wang G, Flynn C, Madden S, MacEneaney O, Cruz R, et al.
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267611
Breast ductal carcinoma in situ (DCIS) is clinically challenging, featuring high diagnosis rates and few targeted therapies. Expression/signaling from junctional adhesion molecule-A (JAM-A) has been linked to poor prognosis in...